Kailera Therapeutics
KLRA
10.53
-0.30
-2.77%
Kailera Therapeutics
US · KLRA
#3073 by market cap
Listed 2026
10.53
-0.30
-2.77%
Live - 5344 symbols - heartbeat 318s ago
· 2026-10-08 07:08
Pre-market
10.68
+1.42%
After-hours
10.53
0.00%
- Market cap
- 1.37B
- P/E (TTM)i
- -4.67
- P/Bi
- 1.22
- EPSi
- -0.01
- Div yieldi
- 0.00%
- 52W posi
- 4%
Reader sentiment
Are you bullish or bearish on KLRA?
Anonymous reader poll. Unscientific, not investment advice.
About Kailera Therapeutics
Kailera Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity. Its product candidate includes Ribupatide. The company was founded on May 08, 2024 and is headquartered in Waltham, MA.
- Founded
- 2024
- CEO
- Mr. Ronald C. Renaud, Jr,M.B.A.
- Employees
- 145
- Headquarters
- Waltham, Massachusetts, United States of America
- Fiscal year end
- 12-31
- Website
- kailera.com
Company profile
- Exchange
- US
- Symbol
- KLRA
- Market-cap rank
- #3073
- Listing date
- 2026-04-17
- Market cap
- 1.37B
- Float cap
- 473.03M
- Shares out
- 129.64M
- Float shares
- 44.92M
Sectors & themes
Quote time 2026-10-08 07:08:07 · For reference only, not investment advice and not tailored to your situation.